Navigation Links
AtriCure Reports Third Quarter 2007 Financial Results


-- Total revenues of $12.1 million - up 29% over third quarter 2006

-- Net loss narrows to $2.6 million - record performance -- Domestic open-heart revenues of $6.7 million - up 22% over third quarter

2006 -- Domestic minimally invasive product revenues of $3.5 million - up 28%

over third quarter 2006

-- Record international revenues of $1.8 million - up 65% over third

quarter of 2006

-- Initial human implants - left atrial appendage clip system

-- Minimally invasive Isolator Synergy(TM) system released

WEST CHESTER, Ohio, Nov. 6 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation systems, today announced revenues of $12.1 million for its third quarter ended September 30, 2007. The net loss for the quarter was $2.6 million, the most favorable performance since becoming a public company.

"We are encouraged by our momentum, operating leverage and overall financial performance during the third quarter. The men and women of AtriCure have amassed greater penetration and stronger market presence in each of our current business sectors. Additionally, we believe that our left atrial appendage clip system will develop into a new business sector and represents a new high growth opportunity for our Company," said David J. Drachman, President and Chief Executive Officer. "We strongly believe that no other atrial fibrillation company is better prepared or positioned than AtriCure to deliver results for patients, physicians and shareholders."

Third Quarter 2007 Financial Results

Third quarter 2007 revenues were $12.1 million, a 28.8% increase over third quarter 2006 revenues of $9.4 million and, impacted by seasonality, a 2.4% decrease as compared to second quarter 2007 revenues of $12.4 million. Revenues from domestic open-heart products were $6.7 million, a 21.9% increase compared to $5.5 million in the third quarter of 2006 and relatively consistent with revenues for the second quarter of 2007. Revenues from domestic minimally invasive products were $3.5 million, representing a 28.0% increase over third quarter 2006 revenues of $2.8 million and a $0.5 million decrease over second quarter 2007 revenues of $4.0 million. International revenues were a record $1.8 million, a 64.6% increase over third quarter 2006 revenues and a 20.3% sequential quarter increase.

Third quarter 2007 gross profit was $9.3 million and gross margin was 77.1%, compared to gross profit of $7.5 million and a gross margin of 79.8% for the third quarter of 2006. The gross margin for the second quarter of 2007 was 79.4%. The decrease in gross margin as compared to the third quarter of 2006 and sequentially, was primarily due to an increased mix of international revenues which generally provide a lower gross margin than domestic revenues, and the introduction of new products which initially drive a higher product cost.

Operating expenses were $12.2 million for the third quarter of 2007 as compared with $10.9 million for the third quarter of 2006. The increase in operating expenses was primarily due to an increase in sales and marketing expenses. The net loss for the third quarter of 2007 was $2.6 million as compared to $3.2 million for the third quarter of 2006 and $2.8 million for the second quarter of 2007. Net loss per share was $0.18 for the third quarter of 2007 as compared with a loss per share of $0.26 for the third quarter of 2006. The net loss for the second quarter of 2007 was $2.8 million, or $0.22 per share.

Cash, cash equivalents and short-term investments were $21.2 million at September 30, 2007 and there were 14.1 million shares of common stock outstanding.

Initial Human Implants - Left Atrial Appendage Clip System

In September 2007, AtriCure's left atrial appendage clip was successfully implanted during an open-heart surgical procedure. To date, as part of a European clinical study, AtriCure's left atrial appendage clip has been successfully implanted in a small series of patients during open-heart surgical procedures in Zurich, Switzerland.

Minimally Invasive Isolator Synergy(TM) System Released

During the quarter, AtriCure released its next generation minimally invasive clamp system, Isolator Synergy(TM). This system incorporates two pulsing pairs of electrodes in the jaws of the clamp. AtriCure believes this enhanced technology allows physicians to ensure full thickness ablations in thicker, more diseased tissues and creates more durable lines of block. The open-heart version was released during the first quarter of 2007 and has been widely adopted.

Financial Guidance

For the full year 2007, the Company is narrowing its revenue guidance range and lowering its net loss per share guidance. The Company expects annual 2007 revenues to be in the range of $48.0 to $48.7 million and net loss per share to be in the range of $0.92 to $0.97 per share. For the fourth quarter 2007, revenues are expected to be between $12.8 and $13.5 million.

Conference Call

AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, November 6, 2007, to discuss third quarter 2007 results. A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at Pre-registration is available for this call at the following URL: Pre- registering is not mandatory, but is recommended as it will provide you immediate entry into the call and will facilitate the timely start of the call. Pre-registration only takes a few moments and you may pre-register at any time, including up to and after the call start time. Alternatively, if you prefer being placed into the call by an operator, please call 888-713-4218 for domestic callers and 617-213-4870 for international callers at least 15 minutes prior to the call start time and use reservation number 91207687.

The web cast will remain available on AtriCure's web site through December 6, 2007. A telephonic replay of the call will also be available until December 6, 2007. The replay numbers are 888-286-8010 for domestic callers and 617-801-6888 for international callers. Please use reservation code 85213467.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation clamps as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(R) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and cardiac related surgical procedures, but to date has not cleared or approved the system for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure's products. Forward-looking statements are based on AtriCure's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.




Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Revenues $12,054,459 $9,358,045 $35,157,448 $27,643,891

Cost of revenues 2,760,418 1,885,946 7,518,066 5,271,104

Gross profit 9,294,041 7,472,099 27,639,382 22,372,787

Operating expenses:

Research and


expenses 2,397,837 3,172,286 8,455,098 9,010,950

Selling, general

and administrative

expenses 9,805,004 7,691,260 30,125,026 23,676,328

Total operating

expenses 12,202,841 10,863,546 38,580,124 32,687,278

Loss from operations (2,908,800) (3,391,447) (10,940,742) (10,314,491)

Other income (loss):

Interest income, net 236,499 235,849 562,141 788,149

Grant income 74,190 - 486,523 72,632

Foreign currency

transaction (loss)

gain (65) - 204,393 -

Net loss $(2,598,176) $(3,155,598) $(9,687,685) $(9,453,710)

Basic and diluted loss

per share $(0.18) $(0.26) $(0.74) $(0.78)

Weighted average

shares outstanding:

Basic and diluted 14,125,230 12,148,565 13,129,204 12,121,044




September 30, December 31,

2007 2006


Current assets:

Cash and cash equivalents $17,230,239 $14,890,383

Short-term investments 3,979,050 4,598,032

Accounts receivable, net 7,362,113 6,562,341

Inventories, net 4,172,069 3,389,401

Other current assets 1,353,415 1,247,738

Total current assets 34,096,886 30,687,895

Property and equipment, net 4,385,978 3,643,069

Intangible assets 1,095,611 772,778

Goodwill 6,222,258 3,840,837

Other assets 141,231 183,486

Total assets $45,941,964 $39,128,065

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued

liabilities $7,087,149 $7,265,424

Current maturities of long-term

debt and capital leases 412,676 391,460

Total current liabilities 7,499,825 7,656,884

Long-term debt and capital leases 384,592 692,544

Other liabilities 334,062 84,375

Total liabilities 8,218,479 8,433,803

Stockholders' equity:

Common stock 14,129 12,189

Additional paid-in capital 103,439,341 86,646,064

Other comprehensive income 12,364 90,673

Accumulated deficit (65,742,349) (56,054,664)

Total stockholders' equity 37,723,485 30,694,262

Total liabilities and stockholders'

equity $45,941,964 $39,128,065




Nine Months Ended September 30,

2007 2006

Cash flows from operating activities:

Net loss $(9,687,685) $(9,453,710)

Adjustments to reconcile net loss

to net cash used in

operating activities:

Depreciation and amortization 1,662,198 1,364,958

Loss (gain) on disposal of

equipment 6,852 (20,000)

Provision for accounts receivable (40,297) 81,420

Share-based compensation expense 1,376,809 649,422

Changes in assets and liabilities:

Accounts receivable (759,473) (1,302,110)

Inventories, net (337,010) (1,114,411)

Other current assets (128,563) (614,958)

Accounts payable and accrued

liabilities (160,272) 364,332

Other non-current assets and

liabilities 255,249 60,988

Net cash used in

operating activities (7,812,192) (9,984,069)

Cash flows from investing activities:

Purchases of property &

equipment, net (2,268,489) (1,378,541)

Proceeds from sale of property &

equipment - 20,000

Purchases of available-for-sale

securities (3,964,561) (5,482,883)

Maturities of available-for-sale

securities 4,608,000 5,365,000

Cash paid for acquisition (3,337,103) -

Net cash used in

investing activities (4,962,153) (1,476,424)

Cash flows from financing activities:

Payments on long-term debt and

capital leases (292,792) (275,468)

Proceeds from stock option exercises 169,873 83,843

Net proceeds from private

placement of common shares 15,317,002 -

Net cash provided by

(used in) financing

activities 15,194,083 (191,625)

Effect of exchange rate changes on cash (79,882) 35,291

Net increase (decrease) in cash and

cash equivalents 2,339,856 (11,616,827)

Cash and cash equivalents - beginning

of period 14,890,383 27,432,948

Cash and cash equivalents - end of

period $17,230,239 $15,816,121

SOURCE AtriCure, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
4. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
7. AtriCure Ranked 80th in Deloittes Technology Fast 500
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... Church, VA (PRWEB) , ... November 24, 2015 , ... ... — 1:30 p.m. – 3:00 p.m. EST, , FDA has long ... regulations. CLIA regulations apply to performing the tests and do not meet the device ...
(Date:11/24/2015)... ... November 24, 2015 , ... In response to recent news highlighting Oxycodone ... prescription opioids in the United States grew 400 percent between 1999 and 2010, far ... involved in 37 percent of all fatal drug overdoses. (1) , While oxycodone and ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s leading provider ... pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is designed to ... The location is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic , ...
(Date:11/24/2015)... Irvine, CA (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC ... Kickstarter last week and hit their goal of $20,000 in under 10 hours. ... aims to bring the new PRO Weight Loss Vest to the market. , The ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... 2015  In the pharmaceutical industry, companies want to ... quickly uncover new insights, tactics and strategies that will ... --> However, organizations often find it is ... ensure that all rules and regulations are met to ... barrier to efficiently launching market research projects is the ...
(Date:11/24/2015)... 2015 --> --> ... Market by Product Type (Bone Graft, Bine Graft Substitute, Platelet ... Posterior Lumbar Interbody Fusion), End User, and Geography - Global ... valued at $1.90 Billion in 2014 and is expected to ... during the forecast period of 2015 to 2020. ...
Breaking Medicine Technology: